This is a snippet of the transcript.Contact Salesto get full access.
Back in the day, if you looked into Nuix, for example, they had a massive ability to analyze data, even better than Cellebrite, with petabytes of information. However, when you examined the link analysis between entities, you saw one email connecting with another email or one mobile device connecting with another mobile device. This doesn't make sense for the investigation or the investigator. I want to see Salim communicating with Adam, not just an email address communicating with another. I also want to see which channels we are using, like WhatsApp or email. This entity resolution, or name resolution, was a big differentiator. It allowed us to put all the digital entities of someone under a single name and make the right correlations, which was quite an intensive project.
This is a snippet of the transcript.Contact Salesto get full access.
This was a very important differentiator for Cellebrite back in the day. We always emphasized that we understood mobile data better and were well-positioned within organizations. From a workflow or process point of view, Cellebrite is there. They are the first thing the police encounter during extraction and examination. If the data goes somewhere else, it's a loss for Cellebrite. It's like Google collecting all the web information and giving it to someone else for analytics. It doesn't make sense for Cellebrite. They are the incumbent, and it's just a matter of making it accessible to the rest of the organization outside of the forensic lab.
This is a snippet of the transcript.Contact Salesto get full access.




This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research



